Augmenta Bioworks


Augmenta Bioworks is dedicated to building global immunity to disease by harnessing natural human immunity to discover new therapeutics. They utilize advanced molecular biology, automation, microfluidics, high throughput DNA sequencing, and computational analysis to identify immune receptors and their antigen specificity, guiding the development of new therapies. They collaborate with pharmaceutical companies, biotech firms, and research institutions to improve vaccine efficacy, discover new antibodies, and develop cell therapies.

Industries

biotechnology
health-care
pharmaceutical

Nr. of Employees

small (1-50)

Augmenta Bioworks

3475 Edison Way Unit K, Menlo Park, CA 94025


Patents

Methods for isolating immune binding proteins

US-11662341-B2

View Details

Immune repertoire sequence amplification methods and applications

US-10858649-B2

View Details

Products

Immune repertoire analysis platform

An integrated discovery platform that combines microfluidics, high-throughput sequencing, laboratory automation, and large-scale computational analysis to identify immune receptors and their antigen specificities.


Services

Collaborative research partnerships to apply immune repertoire profiling and discovery tools to therapeutic programs.

Services to profile changes in immune repertoires after antigen exposure or therapeutic intervention to inform vaccine and immunotherapy programs.

Expertise Areas

  • Immune repertoire analysis
  • Antibody discovery from human repertoires
  • Cell therapy target discovery
  • Vaccine immunomonitoring
  • Show More (4)

Key Technologies

  • Next-generation sequencing
  • Microfluidics
  • Laboratory automation
  • Scalable bioinformatics and computational analysis
  • Show More (3)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.